Published in Clin Colon Rectal Surg on June 01, 2013
Environmental Enteric Dysfunction in Children. J Pediatr Gastroenterol Nutr (2016) 0.80
An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol (2015) 0.75
Septic knee arthritis in Crohn's disease biological therapy-free patient. Case report. J Med Life (2015) 0.75
Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.75
Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease. Dig Dis Sci (2016) 0.75
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 3.41
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med (1980) 3.01
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology (1973) 2.72
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology (2001) 2.69
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med (1994) 2.52
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol (1993) 2.47
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 2.26
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol (2000) 2.03
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97
Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis (2001) 1.95
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 1.74
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2005) 1.73
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol (2004) 1.46
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut (1997) 1.30
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology (2008) 1.19
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2008) 1.14
Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis (2003) 1.11
Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis (1999) 1.10
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2010) 1.07
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther (2010) 1.07
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.05
Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg (2010) 0.99
Azathioprine: old drug, new actions. J Clin Invest (2003) 0.98
Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev (2005) 0.96
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev (2010) 0.89
Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther (2004) 0.88
Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology (2001) 0.86
Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol (2002) 0.83
Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis (2011) 0.82
Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos (1987) 0.81
The long journey of salicylates in ulcerative colitis: The past and the future. J Crohns Colitis (2009) 0.78